IMP3, NESP55, TTF-1 and CDX2 serve as an immunohistochemical panel in the distinction among small-cell carcinoma, gastrointestinal carcinoid, and pancreatic endocrine tumor metastasized to the liver

Applied Immunohistochemistry and Molecular Morphology

Volumn 20, Issue 6, 2012, Pages 573-579

  Denby, Kristopher S ^a   Briones, Alice J ^a,b   Bourne, Patricual A ^a,c   Spaulding, Betsy O ^c   Lu, Dongsi ^d   Fischer Colbrie, Reiner ^e   Qu, Zhenhong ^a,f   Wang, Hanlin L ^g   Xu, Haodong ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c Schering Plough Biopharma ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

^g INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

carcinoid; CDX2; gastrointestinal; IMP3; liver; lung; metastasis; NESP55; pancreatic endocrine tumor; small cell carcinoma; TTF 1

Indexed keywords

IMP3 PROTEIN; NEUROENDOCRINE SPECIFIC PROTEIN; NEUROENDOCRINE SPECIFIC PROTEIN P55; PROTEIN; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG;

ARTICLE; CANCER OF UNKNOWN PRIMARY SITE; CARCINOID; DIAGNOSTIC VALUE; GASTROINTESTINAL CARCINOID; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; IMMUNOREACTIVITY; LIVER METASTASIS; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL CELL CARCINOMA;

CARCINOID TUMOR; CARCINOMA, SMALL CELL; DNA-BINDING PROTEINS; GASTROINTESTINAL NEOPLASMS; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; PANCREATIC NEOPLASMS; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870453976     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3182494009     Document Type: Article

References (19)

1. Du EZ, Goldstraw P, Zacharias J, et al. TTF-1 expression is specific for lung primary in typical and atypical carcinoids: TTF-1-positive carcinoids are predominantly in peripheral location. Hum Pathol. 2004;35:825-831.
2. Barbareschi M, Roldo C, Zamboni G, et al. CDX-2 homeobox gene product expression in neuroendocrine tumors: its role as a marker of intestinal neuroendocrine tumors. Am J Surg Pathol. 2004;28: 1169-1176.
3. Erickson LA, Papouchado B, Dimashkieh H, et al. Cdx2 as a marker for neuroendocrine tumors of unknown primary sites. Endocr Pathol. 2004;15:247-252.
4. Srivastava A, Padilla O, Fischer-Colbrie R, et al. Neuroendocrine secretory protein-55 (NESP-55) expression discriminates pancreatic endocrine tumors and pheochromocytomas from gastrointestinal and pulmonary carcinoids. Am J Surg Pathol. 2004;28:1371-1378.
5. Srivastava A, Hornick JL. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. Am J Surg Pathol. 2009;33: 626-632.
6. Long KB, Srivastava A, Hirsch MS, et al. PAX8 expression in welldifferentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol. 2010;34:723-729.
7. Schmitt AM, Riniker F, Anlauf M, et al. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol. 2008;32:420-425.
8. Jaffee IM, Rahmani M, Singhal MG, et al. Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin. Arch Pathol Lab Med. 2006;130:1522-1526.
9. Saqi A, Alexis D, Remotti F, et al. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am J Clin Pathol. 2005;123:394-404.
10. Mueller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene. 1997;14:2729-2733.
11. Liao B, Hu Y, Herrick DJ, et al. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem. 2005;280:18517-18524.
12. Liao B, Patel M, Hu Y, et al. Targeted knockdown of the RNAbinding protein CRD-BP promotes cell proliferation via an insulinlike growth factor II-dependent pathway in human K562 leukemia cells. J Biol Chem. 2004;279:48716-48724.
13. Xu H, Bourne PA, Spaulding BO, et al. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol. 2007;38:555-563.
14. Simon R, Bourne PA, Yang Q, et al. Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Hum Pathol. 2007;38:1178-1183.
15. Pryor JG, Simon RA, Bourne PA, et al. Merkel cell carcinoma expresses K homology domain-containing protein overexpressed in cancer similar to other high-grade neuroendocrine carcinomas. Hum Pathol. 2009;40:238-243.
16. Yantiss RK, Cosar E, Fischer AH. Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas. Acta Cytol. 2008;52:133-138.
17. Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 2005;29:188-195.
18. Wachter DL, Schlabrakowski A, Hoegel J, et al. Diagnostic value of immunohistochemical IMP3 expression in core needle biopsies of pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2011;35:873-877.
19. Jeng YM, Chang CC, Hu FC, et al. RNA-binding protein insulinlike growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology. 2008;48:1118-1127.